2025 Current Fiscal Year Report: National Vaccine Advisory Committee

Report Run Date: 06/20/2025 05:41:00 AM

| 1. Department or Agency | | | 2. Fiscal Year | | |
|---|--------------------------------|---------|--------------------------|---------------------------------|----------------|
| Department of Health and Human Services | | | 2025 | | |
| 3. Committee or Subcommittee | | | 3b. GSA Committee No. | | |
| National Vaccine | Advisory Comn | nittee | | 971 | |
| 4. Is this New D | uring 5. Curren | t 6.E | xpecte | əd | 7. Expected |
| Fiscal Year? | Charter | Rer | newal [| Date | Term Date |
| No | 07/30/202 | 3 07/3 | 30/202 | 5 | |
| 8b. Specific 8a. Was Terminated During FiscalYear? Authority | | | | 8c. Actual Term Date | |
| No | 42 | U.S.C | : 300a | a-5 | |
| 9. Agency Recommendation for Next FiscalYear | | | | 10b. Legislation Pending? | |
| Continue | No | t Appli | icable | | Not Applicable |
| 11. Establishment Authority Statutory (Congress Created) | | | | | |
| 12. Specific | 13. | | 14. | | 14c. |
| Establishment | Effective Commitee | | nitee | Presidential? | |
| Authority | Date | | Туре | | |
| 42 U.S.C. 300aa | -5 11/14/ | 1986 | Contin | nuing | No |
| 15. Description of Committee National Policy Issue Advisory Board | | | | | |
| 16a. Total Number of Reports | No Reports for this FiscalYear | | | | |
| 17a. 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0 Open | | | | | |
| Meetings and D No Meetings | ates | | | | |
| | | Сι | urrentl | Next | |

| 18a(1). Personnel Pmts to Non-Federal Members | \$0.00\$0.00 |
|--|--------------|
| 18a(2). Personnel Pmts to Federal Members | \$0.00\$0.00 |
| 18a(3). Personnel Pmts to Federal Staff | \$0.00\$0.00 |
| 18a(4). Personnel Pmts to Non-Member Consultants | \$0.00\$0.00 |
| 18b(1). Travel and Per Diem to Non-Federal Members | \$0.00\$0.00 |
| 18b(2). Travel and Per Diem to Federal Members | \$0.00\$0.00 |
| 18b(3). Travel and Per Diem to Federal Staff | \$0.00\$0.00 |
| 18b(4). Travel and Per Diem to Non-member Consultants | \$0.00\$0.00 |
| 18c. Other(rents,user charges, graphics, printing, mail, etc.) | \$0.00\$0.00 |
| 18d. Total | \$0.00\$0.00 |
| 19. Federal Staff Support Years (FTE) | 0.00 0.00 |

20a. How does the Committee accomplish its purpose?

The National Vaccine Advisory Committee (NVAC) was established in 1987 to comply with Title XXI of the Public Health Service Act (P.L. 99-660) (Section 2105) (42 U.S. Code 300aa-5.). The NVAC serves an advisory role, providing peer review, consultation, advice, and recommendations to the Assistant Secretary for Health in his/her capacity as the Director of the National Vaccine Program, on matters related to the Program's responsibilities. Specifically, the committee studies and recommends ways to encourage the availability of an adequate supply of safe and effective vaccination products in the United States; recommends research priorities and other measures to enhance the safety and efficacy of vaccines; and discusses evidence-based strategies for preventing vaccine preventable diseases across all age groups through the use of vaccines. The committee also advises the Assistant Secretary for Health in the implementation of the National Vaccine Plan. The committee meets at least three times per year, usually in a two-day, public meeting that is available as a webcast to those unable to attend in person. Notes from each meeting are transmitted to the Assistant Secretary for Health and posted to the NVAC website at https://www.hhs.gov/vaccines/nvac/index.html. The committee develops reports with recommendations on topics charged by the Assistant Secretary for Health. These reports are available on the HHS website at https://www.hhs.gov/vaccines/nvac/reports-and-recommendations/index.html. The reports and other recommendations voiced in meetings are transmitted to the Assistant Secretary for Health as well.

20b. How does the Committee balance its membership?

The committee consists of 17 voting members. The membership is composed of 15 public members, including the chair, and 2 members who are designated to serve as official representatives of the vaccine manufacturing industry. The public members, who are selected from individuals engaged in various aspects of the vaccine enterprise, include (but are not limited to) physicians, members of organizations concerned with immunization and representatives of state and local health departments or public health organizations. The committee membership also consists of non-voting representatives from appropriate federal agencies and non-federal entities, including state and local health agencies or public health organizations that are engaged in and/or have interest in vaccine research, the manufacture of vaccines, and immunization. Individuals who are appointed to represent federal organizations will serve as ex-officio members. Individuals who are appointed to represent non-federal entities will serve as non-voting liaison representatives. To ensure that the committee membership is fairly balanced in terms of the points of view presented, consideration is given to a broad representation of geographic areas, gender, race, ethnicity, and disability, as well as a broad representation of expertise.

20c. How frequent and relevant are the Committee Meetings?

The committee meets at a minimum three times a year. The committee deliberates and works to close gaps in immunization coverage areas that will have a substantial impact on public health policy and the prevention of infectious diseases and their complications through vaccination, by recommending actions to be taken -- by federal agencies and non-federal stakeholders -- that are involved in vaccine and immunization-related activities. Specifically, the committee offers advice and guidance on how to address existing barriers in the immunization delivery system, including strengthening immunization infrastructure, supporting providers and other partners who provide immunization services, increasing demand for immunization, and fostering vaccine development and innovation in new immunization technologies.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

NVAC's mission, laid out in its charter, is very broad. NVAC is charged with advising the

Assistant Secretary for Health on the entire range of vaccine and immunization policy which requires a depth of specialized expertise such as disease burden, public trust, vaccine access, and other issues affect the immunization system. Through focused and timely input, the committee plays an essential role in providing policy, research, and practice recommendations on pressing immunization issues, such as vaccine confidence, immunization disparities, disease outbreaks, and vaccine safety. NVAC is the only federal advisory committee that considers and makes recommendations across the entire U.S. immunization system, making their work vital to improving the lagging rates of adult immunization, improving equity in vaccination, and ensuring that we continue to immunize at rates high enough to maintain herd immunity and prevent the transmission of vaccine-preventable infectious disease.

20e. Why is it necessary to close and/or partially closed committee meetings?

Full committee meetings are open to the public.

21. Remarks

Designated Federal Officer

Ann L. Aikin Communications Officer

| Committee Members | Start | End | Occupation | Member Designation |
|----------------------|------------|------------|------------------|-----------------------|
| | | | Association of | |
| Allen, | | | State and | Representative |
| Meredith | 09/13/2021 | 07/30/2025 | Territorial | Member |
| Mereditri | | | Officials | Member |
| | | | (ASTHO) | |
| Bobo, | 00/01/2022 | 06/12/2025 | Senior Director, | Representative |
| Matthew | 02/01/2023 | 00/12/2025 | Immunization | Member |

| Bok, Karin | 09/12/2024 | 09/30/2026 | FDA | Regular Government Employee (RGE) Member |
|---------------------|------------|------------|---|--|
| Bok, Karin | 09/12/2024 | 09/30/2026 | FDA | Regular Government Employee (RGE) Member |
| Chukwuma, Uzo | 01/26/2021 | 09/30/2025 | IHS | Regular Government Employee (RGE) Member |
| Coyle, Rebecca | 09/01/2018 | 07/30/2025 | American Immunization Registry Association (AIRA) | Representative Member |
| Diba, Roxanna | 06/29/2022 | 07/30/2025 | HRSA | Regular Government Employee (RGE) Member |
| Duchin, Jeffrey | 02/10/2022 | 02/09/2026 | Seattle & King County Public Health Official | Special Government Employee (SGE) Member |
| Ehresmann, Kris | 06/08/2020 | 12/04/2024 | Epidemiologist | Special Government Employee (SGE) Member Regular |
| Ford, Andrew | 09/12/2024 | 09/30/2026 | NIH | Government Employee (RGE) Member |
| Hance, Mary Beth | 02/08/2024 | 02/28/2026 | CMS | Regular Government Employee (RGE) Member |
| Hannan, Claire | 09/01/2019 | 07/30/2025 | Association of Immunization Managers (AIM) | Representative Member |
| Henry, Erin | 09/13/2023 | 09/26/2025 | Public Health Agency of Canada (PHAC) | Representative Member |
| Hoft, Daniel | 06/08/2020 | 12/04/2024 | Infectious Diseases and Immunology | Special Government Employee (SGE) Member |

| Holbrook, Brenda | 06/13/2024 | 06/19/2026 | HRSA | Regular Government Employee (RGE) Member |
|--------------------------|------------|------------|--|--|
| Howell, Molly | 02/12/2020 | 02/11/2025 | Immunization Program Manager | Special Government Employee (SGE) Member |
| Johnson, Robert | 09/08/2022 | 07/30/2025 | Biomedical Advanced Reseach and Development Authority (BARDA) | Regular Government Employee (RGE) Member |
| Knighton, Troy | 09/01/2018 | 07/30/2025 | VA | Regular Government Employee (RGE) Member |
| Mills, Justin | 09/01/2018 | 07/30/2025 | Agency for Healthcare Research and Quality (AHRQ) | Regular Government Employee (RGE) Member |
| Mullen, Jewel | 02/10/2022 | 02/09/2026 | Associate Dean at Dell Medical School | Special Government Employee (SGE) Member |
| Patel, Mo | 09/13/2023 | 09/30/2025 | CDC | Regular Government Employee (RGE) Member |
| Regal, Chris | 09/01/2018 | 07/30/2025 | America's Health Insurance Plans (AHIP) | Representative Member |
| Rinderknecht, Stephen | 02/10/2022 | 02/09/2026 | Pediatrician | Special Government Employee (SGE) Member |
| Rothholz, Mitchell | 06/03/2023 | 07/30/2025 | American Pharmacists Association (APhA) | Representative Member |
| Schlay, Judy | 06/12/2024 | 06/12/2026 | Professor of Family Medicine | Representative Member |
| Srinivas, Geetha | 04/29/2020 | 07/30/2025 | USDA | Regular Government Employee (RGE) Member |

Number of Committee Members Listed: 28

Narrative Description

The National Vaccine Advisory Committee (NVAC) was established in 1987 to comply with Title XXI of the Public Health Service Act (P.L. 99-660) (Section 2105) (42 U.S. Code 300aa-5). The NVAC serves an advisory role, providing peer review, consultation, advice, and recommendations to the Assistant Secretary for Health in his/her capacity as the Director of the National Vaccine Program, on matters related to the Program's responsibilities. Specifically, the committee studies and recommends ways to encourage the availability of an adequate supply of safe and effective vaccination products in the United States; recommends research priorities and other measures to enhance the safety and efficacy of vaccines. The committee also advises the Assistant Secretary for Health in the implementation of the National Vaccine Plan.

What are the most significant program outcomes associated with this committee?

| | Checked if |
|--------------------------------------|--------------|
| | Applies |
| Improvements to health or safety | ✓ |
| Trust in government | < |
| Major policy changes | |
| Advance in scientific research | \checkmark |
| Effective grant making | |
| Improved service delivery | < |
| Increased customer satisfaction | |
| Implementation of laws or regulatory | |
| requirements | |
| Other | |

Outcome Comments

What are the cost savings associated with this committee?

| | Checked if Applies |
|----------------------------|--------------------|
| None | |
| Unable to Determine | \checkmark |
| Under \$100,000 | |
| \$100,000 - \$500,000 | |
| \$500,001 - \$1,000,000 | |
| \$1,000,001 - \$5,000,000 | |
| \$5,000,001 - \$10,000,000 | |
| Over \$10,000,000 | |
| Cost Savings Other | |

Cost Savings Comments

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

Number of Recommendations Comments

Since FY2007, the committee has approved a total of 414 individual recommendations contained within 36 sets of recommendations. These recommendations are developed through extensive subject-matter input from the NVAC subcommittees, as well as extensive deliberations by the full committee. The focus of these recommendations have included: vaccine safety and confidence; pandemic response; immunization equity; strengthening immunization information systems; improving influenza vaccination uptake in healthcare personnel; and overcoming patient and provider barriers to uptake of recommended vaccines in pregnant women; promoting research and development of vaccines for use in pregnant women. In FY 2024, the NVAC was charged with providing recommendations to inform the development of the next Vaccines National Strategic Plan and continues to work on a charge to improve vaccine innovation.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

36%

% of Recommendations Fully Implemented Comments

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency? 47%

% of Recommendations Partially Implemented Comments

Some recommendations have not been fully implemented due to resource limitations or remain as works in progress. Additionally, because many of the recommendations are complex, only portions have been implemented.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes 🗹 No 🗌 Not Applicable 🗌

Agency Feedback Comments

Feedback is provided during the NVAC meetings during remarks other informational sessions.

What other actions has the agency taken as a result of the committee's advice or recommendation?

| | Checked if Applies |
|-----------------------------------|--------------------|
| Reorganized Priorities | \checkmark |
| Reallocated resources | |
| Issued new regulation | |
| Proposed legislation | |
| Approved grants or other payments | |
| Other | |

Action Comments

NA

Is the Committee engaged in the review of applications for grants? No

Grant Review Comments

How is access provided to the information for the Committee's documentation?

| | Checked if Applies |
|---|--------------------|
| Contact DFO | \checkmark |
| Online Agency Web Site | \checkmark |
| Online Committee Web Site | \checkmark |
| Online GSA FACA Web Site | \checkmark |
| Publications | \checkmark |
| Other | |
| Online Agency Web Site Online Committee Web Site Online GSA FACA Web Site Publications | |

Access Comments

N/A